Why Is NRSN Stock Dropping Today? NeuroSense Therapeutics Falls After 1-for-20 Reverse Split Announcement

NeuroSense Therapeutics (NRSN) shares fell 11.45% in pre-market trading after the company announced a 1-for-20 reverse share split on September 9, 2026. Investors appeared to react to the corporate action, which is often viewed as a warning sign by market participants.

What Did NeuroSense Therapeutics Announce?

The company will consolidate its Nasdaq-listed ordinary shares at a 1-for-20 ratio. That means the number of issued and outstanding shares drops from 37,938,036 to approximately 1,896,902. Trading on a post-split basis begins September 14, 2026.

The authorized share capital remains unchanged. Fractional shares are rounded up, and all outstanding warrants and options are adjusted proportionately. The stock is also assigned a new CUSIP.

Why Does The Reverse Split Matter?

Reverse splits rarely signal operational improvements. They are usually about appearances — raising the nominal share price to meet exchange listing requirements or attract investors who avoid penny stocks.

That context matters here. NeuroSense is a clinical-stage biotech based in Herzliya, Israel, developing targeted therapeutics for neurodegenerative diseases. Its lead candidate, PrimeC, is intended to treat ALS. The company is also running programs for Parkinson's and Alzheimer's diseases.

On August 13, CEO Alon Ben-Noon wrote directly to shareholders, flagging Nasdaq compliance and saying the company was actively working to secure financing for its Phase 3 PARAGON study. The reverse split may be part of that compliance push, but it does not address the underlying need for capital.